NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

9 Months Ended

Jun. 30, 2022

5. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of June 30,		As of September 30,
	2022		2021
Accrued compensation and benefits	$	959,405	$	880,707
Accrued consulting settlement		75,000		200,000
Accrued professional fees		441,116		299,557
Accrued research and development		182,410		297,047
Accrued franchise tax		123,546		30,720
Other accrued expenses		87,383		39,715
Total	$	1,868,860	$	1,747,746